Medicare AdvantageAugust 3, 2023
Specialty pharmacy medical step therapy for hyaluronan injections
The following Part B medications from the current Clinical Criteria Guidelines are included in our medical step therapy precertification review process. Step therapy review will apply upon precertification initiation, in addition to the current medical necessity review (as is current procedure). Step therapy will not apply for members who are actively receiving medications listed below.
There are no clinical changes to Clinical Criteria CC-005, Hyaluronan Injections. Based on feedback, the table listing the preferred and non-preferred products has been updated to present the information in a more useful manner. The updated table identifies preferred alternatives based on injection series.
Clinical Criteria Guidelines are publicly available on the provider website. Visit the Clinical Criteria page to search for specific criteria.
Clinical UM Guidelines | Preferred drug(s) | Nonpreferred drug(s) |
Single injection: Durolane
Three injection series: Euflexxa Gel-Syn
Five injection series: Supartz
| Single injection: Gel-One Monovisc Synvisc-one
Two injection series: Hymovis
Three Injection series: Orthovisc Synojoynt Synvisc Triluron Trivisc
Five injection series: Genvisc 850 Hyalgan Visco-3 |
MULTI-BCBS-CR-031138-23-CPN30365
PUBLICATIONS: September 2023 Provider Newsletter
To view this article online:
Or scan this QR code with your phone